Regional Radiation Therapy with or without Whole Breast Irradiation in Treating Patients with Estrogen Receptor Positive, HER2 Negative Low Risk Breast Cancer Who Have Undergone Breast Conserving Surgery or Mastectomy
Inclusion Criteria
- Patients must be women with newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases, staged as per site standard of care
- Patients must have been treated by breast conserving surgery (BCS) or mastectomy Patients must have been treated by breast conserving surgery (BCS) or mastectomy with clear margins of excision * Patients treated by BCS with focally positive margins for invasive breast cancer or ductal carcinoma in situ (DCIS) (involving < 3 high power fields) are eligible if additional surgery is not possible, e.g. posterior margin positive and deep resection margin abuts the chest wall or anterior margin positive and superficial resection margin abuts the skin; boost radiotherapy must be administered for positive margins as described above
- Post-mastectomy positive margins for invasive breast cancer and/or DCIS is not allowed
- Multifocal disease (i.e. the presence of two or more foci of breast cancer within the same breast quadrant) and multicentric disease (i.e. the presence of two or more foci of breast cancer in different quadrants of the same breast) are allowed
- Patients with T3N0 disease are eligible
- Patients with disease limited to nodal micrometastases are eligible
- Patients with nodal macrometastases (> 2 mm) treated by axillary dissection must have 1-3 positive axillary nodes (macrometastases, > 2 mm) * Note patients with additional nodal micrometastases (> 0.2-2mm) or isolated tumour cells (=< 0.2 mm) are eligible
- Patients with nodal macrometastases (> 2 mm) treated by sentinel lymph node biopsy (SLNB) alone must have only 1-2 positive axillary nodes (macrometastases, > 2 mm) * Note patients with additional nodal micrometastases (> 0.2-2mm) or isolated tumour cells (=< 0.2 mm) are eligible
- Patients must be ER >= 1% and HER2 negative on local testing
- Patients must have an Oncotype DX recurrence score =< 25 obtained from testing of breast tumor tissue from a core biopsy or from the surgical specimen * If the patient does not already have Oncotype DX recurrence score, specimen (unstained blocks or slides) must be sent to the Genomic Health centralized laboratory in Redwood City, California * Oncotype DX testing must be performed on a core biopsy PRIOR to commencement of neoadjuvant endocrine therapy
- Patient must consent to provision of, and investigator(s) must agree to submit to the Canadian Cancer Trials Group (CCTG) Central Tumour Bank, a representative formalin fixed paraffin block of tumor tissue in order that the specific correlative marker assays described in the protocol may be conducted; where tissue exists but local center regulations prohibit submission of blocks of tumor tissue, the approval of the CCTG must be sought prior to randomization of the first patient to allow cores (two 2 mm cores of tumor from the block) and slides (20 x 5 micron thick unstained slides) of representative tumor tissue to be substituted; where tumor tissue is available, failure to submit any tissue samples will result in the patient being considered ineligible
- Patient must consent to provision of samples of blood in order that the specific correlative marker assays described in the protocol may be conducted
- Patients must have had endocrine therapy initiated or planned for >= 5 years; premenopausal women will receive ovarian ablation plus aromatase inhibitor therapy or tamoxifen if adjuvant chemotherapy was not administered; for all patients, endocrine therapy can be given concurrently or following RT
- Patients may or may not have had adjuvant chemotherapy
- RT must be administered within 16 weeks of definitive surgery if the patient is not treated with chemotherapy; if adjuvant chemotherapy is given, RT must begin within 12 weeks after the last dose; (Note: adjuvant chemotherapy may be ongoing at the time of randomization) * Note: Definitive surgery is defined as the last breast cancer-related surgery
- Patient’s Eastern Cooperative Oncology Group (ECOG) performance status must be 0, 1 or 2
- Patient’s age must be >= 35 years
- For the first 736 eligible English or French-speaking subjects who have agreed to optional questionnaire completion: Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life, health utilities and lost productivity questionnaires in either English or French; the baseline assessment must be completed within required timelines, prior to registration/randomization; inability (lack of comprehension in English or French, or other equivalent reason such as cognitive issues or lack of competency) or refusal to complete the questionnaires will not make the patient ineligible for the study; participation in questionnaire completion is mandatory for centers, but optional for patients
- Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements; each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate * A similar process must be followed for sites outside of Canada as per their respective cooperative group’s procedures
- Patients must be accessible for treatment and follow-up; investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up
- In accordance with CCTG policy, protocol treatment is to begin within 6 weeks of patient randomization
- Women of childbearing potential must have agreed to use an effective contraceptive method; a woman is considered to be of "childbearing potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, she is responsible for beginning contraceptive measures * Women of childbearing potential will have a pregnancy test to determine eligibility as part of the Pre-Study Evaluation; this may include an ultrasound to rule-out pregnancy if a false-positive is suspected; for example, when beta-human chorionic gonadotropin is high and partner is vasectomized, it may be associated with tumor production of human chorionic gonadotropin (hCG), as seen with some cancers; patient will be considered eligible if an ultrasound is negative for pregnancy
Exclusion Criteria
- Patients with nodal disease limited to isolated tumour cells (pN0i+ < 0.2 mm)
- Patients with pT3N1 and pT4 disease (Note: patients with T3N0 are eligible)
- Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy; (Patients with synchronous or previous ipsilateral lobular breast carcinoma in situ [LCIS] are eligible)
- Synchronous or previous contralateral invasive breast cancer; (patients with contralateral DCIS are eligible unless previously treated with radiation)
- History of non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers treated by local excision or other cancers curatively treated with no evidence of disease for >= 5 years
- Patients who are pregnant
- Patients that have had prior ipsilateral chestwall/thoracic radiation
- Patients treated with chemo or endocrine therapy administered in the neoadjuvant setting for breast cancer; endocrine therapy exposure 12 weeks or less prior to surgery is permitted
- Patients with serious non-malignant disease (e.g. cardiovascular, scleroderma etc.) which would preclude RT
- Patients with any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator’s decision)
Alaska
Fairbanks
Arizona
Tucson
Arkansas
Little Rock
California
Anaheim
Berkeley
Duarte
Dublin
Fresno
Los Angeles
Napa
Oakland
Orange
Palm Springs
Rancho Cordova
Rohnert Park
Roseville
Santa Clara
Santa Monica
South Pasadena
South San Francisco
Vallejo
Colorado
Aurora
Colorado Springs
Denver
Fort Collins
Golden
Greeley
Highlands Ranch
Littleton
Loveland
Wheat Ridge
Connecticut
Guilford
Hamden
New Haven
Trumbull
Waterford
Delaware
Newark
District of Columbia
Washington
Florida
Boca Raton
Clearwater
Coral Gables
Deerfield Beach
Fort Lauderdale
Hollywood
Jacksonville
Miami
Orlando
Pembroke Pines
Saint Petersburg
Tampa
Weston
Georgia
Savannah
Idaho
Boise
Illinois
Chicago
DeKalb
Decatur
Effingham
Evanston
Geneva
Glenview
Lake Forest
Maywood
Park Ridge
Peoria
Rockford
Springfield
Urbana
Warrenville
Indiana
Avon
Carmel
Fishers
Indianapolis
Muncie
Iowa
Clive
Creston
Des Moines
Kansas
Kansas City
Overland Park
Wichita
Kentucky
Edgewood
Lexington
Louisville
Louisiana
Shreveport
Maine
Bath
Brewer
Portland
Sanford
Scarborough
Maryland
Annapolis
Baltimore
Bethesda
Massachusetts
Boston
Burlington
Lowell
Springfield
Michigan
Ann Arbor
Dearborn
Farmington Hills
Grand Rapids
Kalamazoo
Muskegon
Novi
Royal Oak
Southfield
Traverse City
Troy
Wyoming
Minnesota
Bemidji
Minneapolis
Mississippi
Southhaven
Missouri
Cape Girardeau
Columbia
Kansas City
Lee's Summit
Saint Louis
Montana
Billings
Butte
Great Falls
Nebraska
Omaha
New Hampshire
Concord
Dover
Lebanon
Manchester
New Jersey
Basking Ridge
Englewood
Hamilton
Middletown
Montvale
New Brunswick
Sewell
Somerville
Toms River
New Mexico
Albuquerque
Las Cruces
New York
Bronx
Brooklyn
Commack
Cooperstown
New York
Nyack
Rochester
Stony Brook
Uniondale
West Harrison
North Carolina
Asheville
Durham
Gastonia
North Dakota
Bismarck
Grand Forks
Ohio
Akron
Beachwood
Canton
Chardon
Cleveland
Columbus
Elyria
Grove City
Mentor
Middleburg Heights
Parma
Ravenna
Sandusky
Wadsworth
Westerville
Westlake
Oklahoma
Oklahoma City
Oregon
Corvallis
Portland
Pennsylvania
Bryn Mawr
Carlisle
Chadds Ford
Erie
Farrell
Greensburg
Harrisburg
Jefferson Hills
Lancaster
Mechanicsburg
Media
Monroeville
Newtown Square
Paoli
Philadelphia
Pittsburgh
Reading
Washington
West Reading
Wexford
Willow Grove
Wynnewood
York
Rhode Island
Providence
Warwick
South Carolina
Bluffton
Boiling Springs
Charleston
Greenville
Greenwood
Greer
Hilton Head Island
Seneca
West Columbia
South Dakota
Sioux Falls
Tennessee
Memphis
Texas
Conroe
Dallas
Galveston
Houston
Laredo
League City
San Antonio
Sugar Land
Utah
American Fork
Cedar City
Farmington
Logan
Murray
Ogden
Provo
Saint George
Salt Lake City
South Jordan
Vermont
Berlin
Burlington
Saint Johnsbury
Virginia
Fishersville
Washington
Auburn
Gig Harbor
Tacoma
West Virginia
Morgantown
Wisconsin
Antigo
Appleton
Eau Claire
Grafton
Green Bay
Johnson Creek
Kenosha
La Crosse
Madison
Marinette
Marshfield
Menomonee Falls
Milwaukee
Minocqua
New Richmond
Oak Creek
Oshkosh
Rice Lake
Sheboygan
Stevens Point
Sturgeon Bay
Summit
Two Rivers
Wausau
West Allis
West Bend
Weston
Wisconsin Rapids
Alberta
Calgary
Edmonton
British Columbia
Abbotsford
Kelowna
Prince George
Surrey
Vancouver
Victoria
Manitoba
Winnipeg
New Brunswick
Saint John
Newfoundland
St. John's
Nova Scotia
Halifax
Ontario
Barrie
Hamilton
Kingston
Kitchener
London
Mississauga
Ottawa
Saint Catharines
Sault Ste Marie
Sudbury
Toronto
Quebec
Greenfield Park
Laval
Montreal
Quebec City
Sherbrooke
Saskatchewan
Regina
Saskatoon
PRIMARY OBJECTIVE:
I. To compare the breast cancer recurrence-free interval (BCRFI) between patients that received regional radiation therapy (RT) or not, defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to breast cancer (BC).
SECONDARY OBJECTIVES:
I. To compare the invasive disease-free survival (DFS) between patients that received regional RT or not.
II. To compare the breast cancer mortality between patients that received regional RT or not.
III. To compare the overall survival (OS) between patients that received regional RT or not.
IV. To compare the locoregional recurrence-free interval (LRRFI) between patients that received regional RT or not.
V. To compare the distant recurrence-free interval (DRFI) between patients that received regional RT or not.
VI. To compare the toxicity between patients that received regional RT or not.
VII. To compare arm volume and mobility measurements between patients that received regional RT or not.
VIII. To compare patient reported outcomes (PROs) and the quality of life (QOL) between patients that received regional RT or not.
IX. To compare the cost effectiveness between patients that received regional RT or not.
TERTIARY OBJECTIVES:
I. To establish a comprehensive tumor bank linked to a clinical database for the further study of predictive and prognostic biomarkers in breast cancer.
II. To evaluate the ability of intrinsic subtype measured by immunohistochemistry (IHC) to predict BCRFI, LRRFI, DRFI and the effect of regional RT on these outcomes.
III. To evaluate other radiation sensitivity signatures to prognosticate and predict effect of regional RT.
IV. To describe the prevalence of detectable baseline circulating tumor deoxyribonucleic acid (DNA) (ctDNA) in node positive low risk estrogen receptor (ER) positive breast cancer and evaluate its prognostic ability.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Following breast conserving surgery (BCS), patients receive whole breast irradiation (WBI) daily Monday to Friday for 16-21 or 25-32 fractions. Patients who underwent mastectomy do not receive RT.
ARM 2: Following BCS, patients receive WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) daily Monday to Friday for 16-21 or 25-32 fractions. Patients who have had a mastectomy receive RT to the chest wall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary).
After completion of study treatment, patients are followed up at 2 months (if not receiving RT), 6 and 12 months after randomization, and then annually thereafter for recurrence and toxicity.
Trial Phase Phase III
Trial Type Treatment
Lead Organization
Canadian Cancer Trials Group
Principal Investigator
Timothy Joseph Whelan
- Primary ID CCTG MA.39
- Secondary IDs NCI-2017-02047
- Clinicaltrials.gov ID NCT03488693